Utilization profile of enoxaparin in hospitalized patients with Chronic Kidney Disease in southern Brazil
Braz. J. Pharm. Sci. (Online)
;
56: e18296, 2020. tab, graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1089202
ABSTRACT
Chronic Kidney Disease (CKD) patients usually require the use of anticoagulants for treatment or prevention of thromboembolic diseases. One such commonly used anticoagulant is enoxaparin. However, special attention is advised when using this drug for CKD patients because dosage adjustments may be needed. This prospective observational study was conducted in adult patients (> 18 years) with CKD stages 3 to 5 who were followed-up daily via prescriptions, medical records and laboratory tests. Enoxaparin doses, renal function and adverse drug events (ADEs) were thus monitored. Of the 87 ADEs identified in this study, 56 (64.3%) occurred in patients requiring enoxaparin prescription adjustment. Out of the 9 patients who had severe ADEs, 8 (88.9%) needed enoxaparin prescription adjustment. The results of this study suggest an overall increased risk of major bleeding and ADEs in patients requiring enoxaparin prescription adjustment. Further investigation of alternative dosing regimens in patients with CKD to maintain efficacy while reducing risks is imperative, as are studies on the utility of monitoring anti-factor Xa activity to guide dosing of enoxaparin. In addition, the role of clinical pharmacists in the management of CKD patients is crucial, as dose adjustments are often necessary.
Full text:
Available
Index:
LILACS (Americas)
Type of study:
Observational study
/
Prognostic study
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Braz. J. Pharm. Sci. (Online)
Journal subject:
Farmacologia
/
Teraputica
/
Toxicologia
Year:
2020
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Pontifícia Universidade Católica do Rio Grande do Sul/BR
Similar
MEDLINE
...
LILACS
LIS